David Walter
Cancer Research Horizons
Biography
Cell Biologist and Scientific Leader with 14+ years’ experience specializing in preclinical oncology R&D and novel target discovery. Currently serving as Group Leader at Cancer Research Horizons (CRH) and CRH Lead of the joint AstraZeneca-CRH Functional Genomics Centre. Before joining Cancer Research Horizons in 2019, I led target discovery and validation programmes at Horizon Discovery. I hold a PhD in Cell Biology from the University of Basel, Switzerland, and completed my postdoctoral studies at the University of Copenhagen, Denmark, where my research focused on the role of cell cycle regulators in genome maintenance.
Relevant Publications
- A benchmark comparison of CRISPRn guide-RNA design algorithms and generation of small single and dual-targeting libraries to boost screening efficiencyLukasiak S., Kalinka A., Gupta N., Papadopoulos A., Saeed K., McDermott U., Hannon G.J., Ross-Thriepland D., Walter D., BMC Genomics (2025).
- CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor–driven proteome through PARP7 activityGorelik A., Paulo J.A., Schroeter C.B., Lad M., Shurr A., Mastrokalou C., Siddiqi S., Suyari O., Brognard J., Walter D., Matthews J., Palmer T.M., Gygi S.P., Ahel I., PNAS (2025).
- The genetic and biochemical basis of human leading strand synthesisAgnarelli A., Buckley-Benbow L., Ozgencil M., Lad M., Ampah K.K., Kalinka A., Belan O., Maslen S., Skehel M.J., Walter D., Day M., Bellelli R., Nature Communications (2025).